Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison

WX Qi, L Tang, A He, Z Shen, F Lin… - … Medical Research and …, 2012 - Taylor & Francis
Erlotinib is a low molecular weight, orally active, epidermal growth … the comparative
effectiveness of pemetrexed and erlotinib. … In this study, only one trial conducted by Cappuzzo et al.…

Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non‑small cell lung cancer: A network meta‑analysis

Y Liu, Y Zhang, G Feng, Q Niu… - Experimental and …, 2017 - spandidos-publications.com
… rates compared with erlotinib (P<0.05). Erlotinib resulted in a significantly longer MST
compared with gefitinib and icotinib (P<0.05). In conclusion, gefitinib, erlotinib and icotinib had …

… advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

MX Li, H He, ZH Ruan, YX Zhu, RQ Li, X He, BH Lan… - BMC cancer, 2017 - Springer
… with erlotinib compared with gefitinib. If confirmed, our results indicate that erlotinib may
play an important role in controlling CNS progression from EGFR mutation-positive NSCLC. …

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy

ST Kim, JE Uhm, J Lee, J Sun, I Sohn, SW Kim… - Lung Cancer, 2012 - Elsevier
… In summary, this study demonstrated that both gefitinib and erlotinib showed effective anti-tumor …
Further study with inclusion of both gefitinib and erlotinib in a properly conducted and …

Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis

W Zhang, Y Wei, D Yu, J Xu, J Peng - BMC cancer, 2018 - Springer
… Almost all of the included studies did not show any differences in all anti-… study reported an
unfavorable result for erlotinib, with both lower PFS and OS, which might relate to the erlotinib

A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice

P Slobbe, AD Windhorst, M Stigter-van Walsum… - EJNMMI research, 2015 - Springer
… suggest that the in vivo tumor uptake of [ 11 C]erlotinib and [ 18 … might be that in the current
study, [ 11 C]erlotinib and [ 18 F]… of [ 11 C]erlotinib and [ 18 F]afatinib in PET studies under …

Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis

W Zhang, Y Wei, D Yu, J Xu, J Peng - Medicine, 2018 - journals.lww.com
studies showed no differences in all indices of antitumor effectiveness, which was the basis
of our results. Only one study reported an unfavorable result against erlotinib, … in the erlotinib

Comparison of therapeutic efficacy of gefitinib and erlotinib in patients with squamous cell lung cancer

HJ Shin, TO Kim, HW Kang, SY Chi… - Tuberculosis and …, 2011 - koreascience.kr
Comparative studies have reported the efficacy of two types of EGFR-TKIs5-8, but there are
not a great number of studies that have compared between gefitinib and erlotinib in patients …

Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung …

JB Auliac, C Chouaid, L Greiller, I Monnet, H Le Caer… - Lung cancer, 2014 - Elsevier
… followed by erlotinib has promising activity in previously treated patients [19], [20], [21], [22]. …
this study was to assess the efficacy and tolerability of second-line sequential erlotinib plus …

[HTML][HTML] Comparative metabolomic analysis of HPAC cells following the acquisition of erlotinib resistance

S Lee, WJ Jang, B Choi, SH Joo… - Oncology …, 2017 - spandidos-publications.com
… In the current study, erlotinib-resistant human pancreatic adenocarcinoma cells (… erlotinib.
To achieve this, the metabolic characteristics between erlotinib-sensitive (HPAC) and erlotinib-…